Armata Pharma Q3 net loss $5.5M; Phase 2 Tail wind enrolled, topline data expected by year-end

Armata Pharmaceuticals, Inc.

2024-Q3 EPS reported -$0.60

Net loss $5.5M ($0.15/share) vs $31.2M loss in Q3 2023; includes $6.9M non-cash gain on convertible debt.
Grant revenue $3.0M (DoD/MTEC) vs $1.2M; R&D expense $9.5M; cash $17.1M as of Sep 30, 2024.
Phase 2 Tail wind (inhaled AP-PA02 for NCFB) enrollment complete; topline data expected by year-end 2024.
Phase 1b/2a diSArm (IV AP-SA02 for S. aureus bacteremia) enrollment complete; topline data Q1 2025.
Extended convertible debt and credit agreement maturity to Jan 10, 2026; appointed David House SVP Finance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.